基于外周血自然杀伤细胞生物标志物的膀胱癌免疫风险分层
研究比较132例膀胱癌、201例其他实体瘤、164例浆细胞疾病与615名健康高加索人的KIR/HLA配体基因型,并用流式细胞术评估外周血NK细胞CD226表达。识别出低、中、高三个免疫风险组,其10年无进展率与生存率差异显著,免疫风险分层对生存具有独立于组织学分期的预后价值。
要点
- 基于KIR/HLA-I基因型和CD226表达可将膀胱癌分为低、中、高三个免疫风险组。
- 三组10年无进展率与生存率差异显著,高风险组预后最差。
- 免疫风险分层对生存的预后价值独立于组织学分期。
核心结论
- 免疫风险分层可补充膀胱癌组织病理学,改善风险分层并指导个体化治疗选择。
- 理解NK细胞肿瘤免疫监视的分子机制将有助于开发未来基于NK细胞的疗法。
研究设计与样本
- 比较132例膀胱癌、201例其他实体瘤、164例浆细胞疾病与615名健康高加索人的KIR/HLA配体基因型。
- 采用流式细胞术评估外周血NK细胞CD226表达。
- 采用卡方、方差分析/事后检验、Kaplan-Meier/对数秩检验和回归分析比较各组、各分期、各治疗及无进展生存与总生存。
主要发现
- 低风险组(KIR2DL1-L2+L3-/C1C1-和KIR2DL1+L2+L3+/C1C1+)、中风险组(其余)和高风险组(KIR2DL5+/HLA-C*16+和KIR2DL1+L2+L3-)的10年无进展率分别为83.3%、48.6%和0%(p<0.001),生存率分别为83.3%、54.3%和6.2%(p<0.001),见于肌层浸润性T2/T4。
- 接受BCG治疗的NMIBC-T1患者中,三组10年无进展率分别为100%、81.6%和50%(p<0.05)。
- 免疫风险分层对生存的预后价值独立于单纯组织学分期(风险比=2.93,p<0.00001,Harrell C统计量=0.779)。
- 外周血NK细胞CD226表达改善中风险T1-T4膀胱癌患者的免疫分层,CD226高表达与低表达者生存率分别为94.1%和66.7%(p<0.05)。
临床怎么用
- 原文结论认为免疫风险分层可补充膀胱癌组织病理学以改善风险分层并指导个体化治疗选择。
- 原文患者摘要指出该外周血检测有助于理解膀胱癌免疫防御机制、对患者风险分类有用并将指导个体化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bladder cancer (BC) is highly immunogenic. Bacillus Calmette-Guérin (BCG) immunotherapy offers the best results in non-muscle-invasive BC (NMIBC). Natural killer cells (NKcs) play decisive roles in BCG-mediated immune response and in general cancer immune-surveillance. OBJECTIVE: To analyze killer-cell immunoglobulin-like receptors (KIRs), their human leukocyte antigen class-I (HLA-I) ligands, and the expression of DNAX Accessory Molecule-1 (DNAM-1/CD226) on peripheral blood (PB) NKcs, to identify useful predictive biomarkers in BC. DESIGN, SETTING, AND PARTICIPANTS: KIR/HLA-ligand genotypes were compared between 132 BC, 201 other solid cancers, 164 plasma cell disorders, and 615 healthy Caucasoid controls. CD226 expression was evaluated by flow cytometry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: KIR/HLA-I interactions and CD226 expression on NKcs (CD226high or CD226low) were compared across study groups, cancer stages, treatments, and progression-free and overall survival of patients, using chi-square, analysis of variance/post hoc, Kaplan-Meier/log-rank, and regression analyses. RESULTS AND LIMITATIONS: Three immunological risk groups were identified: low risk (KIR2DL1-L2+L3-/C1C1- and KIR2DL1+L2+L3+/C1C1+), intermediate risk (rest), and high risk (KIR2DL5+/HLA-C*16+ and KIR2DL1+L2+L3-), which displayed different 10-yr progression-free rates (83.3%, 48.6%, and 0%, respectively; p<0.001) and survival rates (83.3%, 54.3%, and 6.2%, respectively; p<0.001) for muscle-invasive T2/T4, and 10-yr progression-free rates (100%, 81.6%, and 50%, respectively; p<0.05) for NMIBC-T1 treated with BCG. Immunological risk stratification had an independent prognostic value to just histological staging for survival (hazard ratio=2.93, p<0.00001, Harrell C-statistic=0.779). CD226 expression on PB NKcs improved immunological stratification in intermediate-risk T1-T4 BC patients, with survival rates of 94.1% and 66.7% for CD226high and CD226low (p<0.05), respectively. CONCLUSIONS: Immunological risk stratification will complement BC histopathology to improve risk stratification and guide the selection of personalized treatments. Understanding of the molecular mechanisms of NKc tumor immune surveillance will enable the development of future NKc-based therapies. PATIENT SUMMARY: This work describes a peripheral blood test that aids in our understanding of the immune defense mechanisms against bladder cancer, is useful for classifying patient risk, and will guide personalized treatments.
引用
- Guillamón CF, Gimeno L, Server G, et al. Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers. Eur Urol Oncol. 2019. PMID: 31411976. doi:10.1016/j.euo.2019.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。